Tsai-Yu Lin

Dr. Tsai-Yu Lin

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2010 in Nature
Verified
Journal Article
Open access
PDF file
SDStephane Daffis
Stephane Daffis
KSKristy J. Szretter
Kristy J. Szretter
JSJill Schriewer
Jill Schriewer
JLJianqing Li
Jianqing Li
SYSoonjeon Youn
Soonjeon Youn
MDMichael Diamond
Michael Diamond
Many cellular messenger RNAs and viral RNAs are methylated at the 2′-O position of the 5′ guanosine cap. The role of this modification in virus infection has been unclear. Michael Diamond and colleagues now show that this form of methylation enables several unrelated viruses to evade innate host antiviral responses through escape from suppression by interferon-stimulated genes. This suggests an evolutionary explanation for 2′-O methylation of cellular mRNA: it may distinguish self from non-self RNA under conditions of infection. Novel classes of pharmacological agents that specifically inhibit cytoplasmic viral 2′-O methyltransferases may be expected to have broad-spectrum antiviral activity. Many cellular and virus messenger RNAs are methylated at the 2′-O positions of the 5′ guanosine cap. The role of 2′-O methylation in virus infection has been unclear. These authors show that this form of methylation enables several unrelated viruses to evade the antiviral effects of genes stimulated by type I interferon. Cellular messenger RNA (mRNA) of higher eukaryotes and many viral RNAs are methylated at the N-7 and 2′-O positions of the 5′ guanosine cap by specific nuclear and cytoplasmic methyltransferases (MTases), respectively. Whereas N-7 methylation is essential for RNA translation and stability1, the function of 2′-O methylation has remained uncertain since its discovery 35 years ago2,3,4. Here we show that a West Nile virus (WNV) mutant (E218A) that lacks 2′-O MTase activity was attenuated in wild-type primary cells and mice but was pathogenic in the absence of type I interferon (IFN) signalling. 2′-O methylation of viral RNA did not affect IFN induction in WNV-infected fibroblasts but instead modulated the antiviral effects of IFN-induced proteins with tetratricopeptide repeats (IFIT), which are interferon-stimulated genes (ISGs) implicated in regulation of protein translation. Poxvirus and coronavirus mutants that lacked 2′-O MTase activity similarly showed enhanced sensitivity to the antiviral actions of IFN and, specifically, IFIT proteins. Our results demonstrate that the 2′-O methylation of the 5′ cap of viral RNA functions to subvert innate host antiviral responses through escape of IFIT-mediated suppression, and suggest an evolutionary explanation for 2′-O methylation of cellular mRNA: to distinguish self from non-self RNA. Differential methylation of cytoplasmic RNA probably serves as an example for pattern recognition and restriction of propagation of foreign viral RNA in host cells.

1 November 2013 in Cell Reports
Verified
Journal Article
Open access
TLTsai-Yu Lin
Tsai-Yu Lin
CCChristopher R. Chin
Christopher R. Chin
AEAaron R. Everitt
Aaron R. Everitt
SCSimon Clare
Simon Clare
JPJill M. Perreira
Jill M. Perreira
ABAbraham L. Brass
Abraham L. Brass
The IFITMs inhibit influenza A virus (IAV) replication in vitro and in vivo. Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication. Consistent with its neutralization of IFITM3, a clinical preparation of AmphoB, AmBisome, reduces the majority of interferon's protective effect against IAV in vitro. Mechanistic studies reveal that IFITM1 decreases host-membrane fluidity, suggesting both a possible mechanism for IFITM-mediated restriction and its negation by AmphoB. Notably, we reveal that mice treated with AmBisome succumbed to a normally mild IAV infection, similar to animals deficient in Ifitm3. Therefore, patients receiving antifungal therapy with clinical preparations of AmphoB may be functionally immunocompromised and thus more vulnerable to influenza, as well as other IFITM3-restricted viral infections.

1 August 2010 in Cell Host & Microbe
Verified
Journal Article
Closed access
AFAnja Fuchs
Anja Fuchs
TLTsai-Yu Lin
Tsai-Yu Lin
DBDavid W. Beasley
David W. Beasley
Cordula StoverCordula Stover
Cordula Stover
WSWilhelm J. Schwaeble
Wilhelm J. Schwaeble
MDMichael Diamond
Michael Diamond

12 October 2006 in Retrovirology
Verified
Journal Article
Open access
TLTsai-Yu Lin
Tsai-Yu Lin
MEMichael Emerman
Michael Emerman
The capsid (CA) protein of HIV-1 binds with high affinity to the host protein cyclophilin A (CypA). This binding positively affects some early stage of the viral life-cycle because prevention of binding either by drugs that occupy that active site of cyclophilin A, by mutation in HIV-1 CA, or RNAi that knocks down intracellular CypA level diminishes viral infectivity. The closely related lentivirus, SIVcpz also binds CypA, but it was thought that this interaction was limited to the HIV-1/SIVcpz lineage because other retroviruses failed to interact with CypA in a yeast two-hybrid assay. We find that diverse lentiviruses, FIV and SIVagmTAN also bind to CypA. Mutagenesis of FIV CA showed that an amino acid that is in a homologous position to the proline at amino acid 90 of HIV-1 CA is essential for FIV interactions with CypA. These results demonstrate that CypA binding to lentiviruses is more widespread than previously thought and suggest that this interaction is evolutionarily important for lentiviral infection.

21 September 2016 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LGLeslie Goo
Leslie Goo
KDKimberly A. Dowd
Kimberly A. Dowd
TLTsai-Yu Lin
Tsai-Yu Lin
JMJohn R. Mascola
John R. Mascola
BGBarney S. Graham
Barney S. Graham
TPTheodore C. Pierson
Theodore C. Pierson
Chikungunya virus (CHIKV) is an alphavirus that has emerged as a global health burden. There are 3 CHIKV genotypes: Asian, West African, and Eastern/Central/South African. No licensed CHIKV vaccine is available, and whether the antibody response elicited by one genotype can neutralize heterologous genotypes is unclear. We assessed neutralizing antibody (NAb) responses of volunteers in a phase 1 study of a CHIKV vaccine against 9 viral strains representing all 3 genotypes. Minimal differences in vaccine-elicited NAb responses were observed among genotypes, suggesting that vaccination with a single CHIKV strain can elicit cross-protective NAbs against all 3 genotypes.

1 December 2014 in Biomaterials
Verified
Journal Article
Closed access
CKChang Seok Ki
Chang Seok Ki
TLTsai-Yu Lin
Tsai-Yu Lin
MKMurray Korc
Murray Korc
Chien-Chi LinChien-Chi Lin
Chien-Chi Lin